• China’s National Medical Products Administration approved Galderma’s Relfydess for temporary improvement of moderate-to-severe frown lines in adults.
• The approval expands the treatment’s reach beyond more than 35 markets where it is already authorized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.